PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Дата публикации: 17-09-2026 00:00:00

This nonrandomized clinical trial examines the efficacy and safety of PDS0101 in combination with pembrolizumab in human papillomavirus 16–positive resistant/metastatic head and neck squamous cell carcinoma.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer	0	8.64	01-08-2026
2	Is Antigen-Specific Immunotherapy a New Frontier in HPV-Initiated Head and Neck Cancer?	0	10.94	17-09-2026
3	Immunotherapy in Head and Neck Squamous Cell Carcinoma With PD-L1 Combined Positive Score of Less Than 1	0	12.19	17-09-2026
4	Pembrolizumab Plus Chemotherapy for Cervical Cancer	0	14.76	10-09-2026
5	Pathological response and exploratory assessment of pretreatment PD-L1 combined positive score after four cycles of neoadjuvant pembrolizumab plus chemotherapy in locally advanced head and neck squamous cell carcinoma: a retrospective cohort study	0	13.96	07-08-2026
6	Serum and Tumor PD-L1 Expression and Aggressive Clinicopathologic Features in Papillary Thyroid Carcinoma	0	12.37	13-08-2026
7	Cost-Effectiveness of Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer	0	7	02-07-2026
8	Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma	0	13.22	28-11-2023
9	FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer	5	5	08-07-2026
10	Pathologic Response After Neoadjuvant Chemoimmunotherapy in Head and Neck Squamous Cell Carcinoma	0	4.44	13-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.08. Источник: jamanetwork.com.